Onika T. Murray, Ph.D.
Affiliations: | 2012 | Molecular and Cellular Pharmacology | Stony Brook University, Stony Brook, NY, United States |
Area:
Pharmacology, Molecular BiologyGoogle:
"Onika Murray"Mean distance: (not calculated yet)
Parents
Sign in to add mentorBasil Rigas | grad student | 2012 | SUNY Stony Brook | |
(Phospho-Sulindac Inhibits Pancreatic Cancer Growth: The Role of NFATc1.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Murray OT, Wong CC, Vrankova K, et al. (2014) Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. International Journal of Oncology. 44: 521-9 |
Xie G, Nie T, Mackenzie GG, et al. (2012) The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. British Journal of Pharmacology. 165: 2152-66 |
Murray OT, Vrankova K, Johnson F, et al. (2012) Abstract 4431: NFATc1 silencing increases sensitivity of pancreatic cancer cells to phosphosulindac Cancer Research. 72: 4431-4431 |
Zhao W, Mackenzie GG, Murray OT, et al. (2009) Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis. 30: 512-9 |